{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-001673","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.152605+00:00","generated_at":"2026-06-20T18:24:16.833827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell reports Q4 2022 preliminary sales down 28% YoY; full year down 3.5%","bullets":["Q4 2022 sales $3.91M vs $5.44M in Q4 2021, a decline of 28.2%.","FY2022 sales $18.57M vs $19.24M in FY2021, down 3.5%.","Backlog $2.5M as of Dec 31, 2022, up from $205k at Sep 30, 2022, similar to $2.4M a year ago.","Production equipment delays and Q3 contamination events prolonged backlog and reduced output.","Expects to submit Re-Tain CMC Technical Section to FDA in Q1 2023 with 6-month review."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-001673","json":"https://secwatch.observer/filing/0001213900-23-001673.json","markdown":"https://secwatch.observer/filing/0001213900-23-001673.md","text":"https://secwatch.observer/filing/0001213900-23-001673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/0001213900-23-001673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/ea171435-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:24:16.833827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f08dda21f4edcfd3c9bba7de2787ca9c9b4d31fa","claim":"IMMUCELL CORP /DE/ reported for the year ended December 31, 2022 results: revenue $18.57 million.","evidence_excerpt":"(% Decrease) During the Three-Month Periods Ended December 31, $ 3.91 million $ 5.44 million $ (1.53 million) (28.2 )% During the Twelve-Month Periods Ended December 31, $ 18.57 million $ 19.24 million $ (675,000 ) (3.5 )% As of December 31, 2022, there was a backlog of orders equal to approximately $2.5 million, representing an increase from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/0001213900-23-001673-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2022"},{"label":"Revenue","value":"$18.57 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}